Table 1.
Participant characteristics. Group: 1 = immediate treatment; 2 = waitlist control. Levodopa equivalent dosage was determined according to Pahwa et al., 1997.32
| ID | Age (years) | Group | Gender | UPDRS-III | Hoehn & Yahr Stage | Disease Duration (years) | Levodopa Equivalent Dosage (mg) | Number of Absences in Yoga Sessions |
|---|---|---|---|---|---|---|---|---|
| 1 | 72 | 2 | M | 14 | 2 | 6 | 450 | 0 |
| 2 | 58 | 2 | F | 16 | 2 | 2 | 50 | 2 |
| 3 | 67 | 1 | F | 14 | 1 | 3 | 150 | 2 |
| 4 | 66 | 2 | F | 23 | 2 | 3.5 | 750 | 2 |
| 5∗ | 74 | 2 | M | – | 3 | 4 | 1000 | – |
| 6 | 57 | 1 | F | 14 | 3 | 13 | 1075 | 14 |
| 7 | 73 | 2 | M | 24 | 3 | 7 | 500 | 3 |
| 8 | 49 | 1 | F | 16 | 1 | 0.75 | 0 | 2 |
| 9 | 75 | 1 | M | 11 | 2 | 2.5 | 300 | 5 |
| 10 | 62 | 1 | M | 14 | 2 | 3 | 700 | 0 |
| 11 | 68 | 2 | F | 22 | 1 | 6 | 400 | 2 |
| 12 | 69 | 2 | M | 14 | 1 | 5.5 | 2386 | 3 |
| 13 | 66 | 1 | F | 13 | 2 | 4 | 300 | 0 |
| 14 | 62 | 1 | F | 23 | 3 | 1.5 | 425 | 2 |
| 15∗ | 63 | 2 | F | 28 | 3 | 10 | 800 | 17 |
| 16 | 55 | 2 | F | 34 | 3 | 5.5 | 500 | 6 |
| 17 | 55 | 1 | M | 20 | 3 | 7 | 1368 | 3 |
| 18 | 76 | 1 | M | 24 | 3 | 4 | 450 | 1 |
| 19 | 60 | 2 | M | 23 | 2 | 1.5 | 300 | 3 |
| 20 | 66 | 1 | M | 26 | 2 | 2.5 | 0 | 0 |
Note: ∗ indicates participants who dropped the study for medical reasons unrelated to this study after recruitment.